Providing market research reports, industry analysis, company profiles and country reports for strategic planning, competitive intelligence, marketing and business research.
Search for Market Research Reports:    

The Commercial Success of Cancer Therapeutic Antibodies - The Formation of a Second Wave

Published by: BioSeeker Group AB

Published: Nov. 22, 2005


Table of Contents


1. Executive Summary

2 Cancer Highlights

3 Methodology

4 4.1 List of Boxes

4.2 List of Tables

5 Key Developmental Strategies

6 Treating Colorectal Cancer

6.1 Avastin

6.1.1 Avastin -Major Developmental Milestones

6.1.2 Sales Predictions on Avastin

6.1.3 Avastin Related Studies

6.2 Erbitux

6.2.1 Erbitux -Major Developmental Milestones

6.2.2 Sales Predictions on Erbitux

6.2.3 Erbitux Related Studies

7 Treating Lymphomas

7.1 Rituxan

7.1.1 Sales Predictions on Rituxan

7.1.2 Rituxan -Major Developmental Milestones

7.1.3 Rituxan Related Studies

7.2 Bexxar

7.2.1 Sales Predictions on Bexxar

7.2.2 Bexxar -Major Developmental Milestones

7.2.3 Bexxar Related Studies

7.3 Zevalin

7.3.1 Sales Predictions on Zevalin

7.3.2 Zevalin -Major Developmental Milestones

7.3.3 Zevalin Related Studies

8 Treating Leukemias

8.1 ALL

8.2 CLL

8.3 AML

8.4 CML

8.5 Campath

8.5.1 Campath -Major Developmental Milestones

8.5.2 Campath Related Studies

8.6 Mylotarg

8.6.1 Mylotarg Related Studies

9 Treating Lung cancer

9.1 Cotara

10 Antibody Deals on the Rise

10.1 Antibody Deals in Phase III

10.1.1 Deal Situation: MDX 010

10.1.2 Deal Situation: WX G250

10.1.3 Deal Situation: Zanolimumab

10.2 Antibody Deals in Phase II

10.2.1 Deal Situation: Mapatumumab

10.2.2 Deal Situation: GCR 3888

10.2.3 Deal Situation: MDX 070

10.2.4 Deal Situation: CDP 860

10.2.5 Deal Situation: Tru-Scint OV

10.2.6 Deal Situation: SC 1

10.2.7 Deal Situation: PRO 70769

10.2.8 Deal Situation: XR 303

10.2.9 Deal Situation: HumaRAD-HN

11 New Approaches in Antibody Delivery and Design The Next Generation

11.1 How to Make Them Smaller and Different?

11.2 Biomaterials in Sustained Delivery Applications

11.2.1 Implants

11.3 Gene delivery the Future?

11.3.1 Delivery Vehicles for DNA

11.3.2 Gene Delivery in Commercialization

12 Current Analysis of Mabs in Clinical Development

12.1.1 Prostate Cancer Therapeutics

12.1.2 Breast Cancer Therapeutics

12.1.3 Colorectal Cancer Therapeutics

12.1.4 Melanoma Therapeutics

12.1.5 Hematological Cancers Therapeutics

12.2 Mabs in Late Stage of Development

12.2.1 MAbs in Phase III Clinical Development

12.2.2 Mabs in Phase II Clinical Development

13 Appendix I: Cancer Therapeutic Antibodies in Clinical Development

14 Appendix II: Discontinued Projects - A Five Year Recapitulation

15 Appendix III: Selected Company Profiles

16 Disclaimer

17 Drug Index

18 Company Index

4.1 List of Boxes

Box 1: The Principal Terms of Deal between AstraZeneca and Cambridge Antibody Technology

Box 2: Marrion’s Drug Delivery Technology

Box 3: Quick Facts - CeaVac.

Box 4: Quick Facts - Elsilimomab

Box 5: Quick Facts IGN 101

Box 6: Quick Facts IMC-BEC2

Box 7: Quick Facts MDX 010

Box 8: Quick Facts ONYVAX 105

Box 9: Quick Facts - Ovare

Box 10: Quick Facts Panitumumab

Box 11: Quick Facts - RENCARNEX.

Box 12: Quick Facts - Nimotuzumab

Box 13: Quick Facts - RENCARNEX

Box 14: Quick Facts - Lintuzumab

Box 15: Quick Facts - Zanolimumab

Box 16: Quick Facts ABT-510

Box 17: Quick Facts BB 10901

Box 18: Quick Facts CP-675206

Box 19: Quick Facts CNTO-328

Box 20: Quick Facts - Ecromeximab

Box 21: Quick Facts EMD-273063

Box 22: Quick Facts WX-G250RIT

Box 23: Quick Facts HGS-ETR1. 97

Box 24: Quick Facts HuMax-CD20

Box 25: Quick Facts HuMax-EGFr2

Box 26: Quick Facts Galiximab

Box 27: Quick Facts PROXINIUM

Box 28: Quick Facts RAV12

Box 29: Quick Facts SGN-15

Box 30: Quick Facts SGN-30

Box 31: Quick Facts VEGF-Trap

Box 32: Quick Facts MEDI 522

Box 33: Quick Facts Volociximab.

Box 34: Quick Facts Zanolimumab

4.2 List of Tables

Table 1: Summary of Strategies Enhancing Antibody Function

Table 2: Potential Advantages in Local, Controlled-Release for Therapeutic Antibodies

Table 3: Drug Delivery Companies with Cancer Focus

Table 4: FDA Approved Polymer-based Drug Delivery Systems for Cancer

Table 5: Antibody Therapeutics in Prostate Cance

Table 6: Antibody Therapeutics in Breast Cancer

Table 7: Antibody Therapeutics in Colorectal Cancer

Table 8: Antibody Therapeutics in Melanoma

Table 9: Antibody Therapeutics in Hematological Cancer

Table 10: MDX-010’s Collaborative History and Landscape

Abstract

Executive Summary
Full Title: The Commercial Success of Cancer Therapeutic Antibodies - The Formation of a Second Wave

Introduction

The blockbuster drugs Rituxan, Avastin, and Erbitux have change the way the industry looks upon antibody treatment of cancer in the same way that Taxol changed the way pharmaceutical companies look at the possibilities in the field of cancer therapeutics.

Scope of this report
  • Thorough examination of the top eight cancer therapeutic antibodies on the market.
  • The race towards the next generation of therapeutic antibodies and improved drug delivery methods there of.
  • Antibody deals are on the rise, where of those targeting oncology is the single most active area.
  • Discussion of the challenges in current drug development, including future clinical trials to be made, collaborations and inclusion of novel endpoints.
Research and analysis highlights

The commercial and therapeutic success of antibodies will force the industry to look into the next generation of therapeutic antibodies, preparing themselves for the second wave in the lucrative field of therapeutic antibodies. The first-generation formulations of therapeutic antibodies will be facing heavy competition from biogeneric companies as their profitable antibody drugs comes off patent in the future. Among the different strategies (e.g., antibody engineering, changes in primary structure, fusions, chemical modifications glycosylation, pegylation, polymer conjugates), the approach of miniaturizing and delivering antibody drugs is the most promising because it permits better release of active drugs.

Key reasons to read this report
  • One source to the top cancer therapeutic antibodies on the market.
  • Key insights into the second wave in the lucrative field of therapeutic antibodies.
  • Competitive landscape assessment, including deals, technologies and more than 100 companies in the field and close to 100 cancer therapeutic antibodies.


Get Full Details About This Report >>
US: 800.298.5699
Int'l: +1.240.747.3093
Buy this Report

Price and Delivery Options
See related reports or call the number above for help from a research specialist.


 

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 300,000 market research reports, company profiles and country profiles from over 700 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

 

© MarketResearch.com 2012
2/14/2012 - 32